Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma
MEM Dolman, E Poon, ME Ebus, IJM den Hartog… - Clinical Cancer …, 2015 - AACR
Purpose: MYCN-dependent neuroblastomas have low cure rates with current multimodal
treatment regimens and novel therapeutic drugs are therefore urgently needed. In previous …
treatment regimens and novel therapeutic drugs are therefore urgently needed. In previous …
Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis
H Husson, S Moreno, LA Smith… - Human molecular …, 2016 - academic.oup.com
Polycystic kidney diseases (PKDs) comprise a subgroup of ciliopathies characterized by the
formation of fluid-filled kidney cysts and progression to end-stage renal disease. A …
formation of fluid-filled kidney cysts and progression to end-stage renal disease. A …
The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model
H Sallam, AT El-Serafi, E Filipski… - Chronobiology …, 2015 - Taylor & Francis
Roscovitine is a selective Cdk-inhibitor that is under investigation in phase II clinical trials
under several conditions, including chemotherapy. Tumor growth inhibition has been …
under several conditions, including chemotherapy. Tumor growth inhibition has been …
Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer
JM Hermanowicz, B Kalaska, K Pawlak, B Sieklucka… - Pharmaceutics, 2021 - mdpi.com
MM-129 is a novel inhibitor targeting BTK/PI3K/AKT/mTOR and PD-L1, as it possesses
antitumor activity against colon cancer. To evaluate the safety profile of MM-129, we …
antitumor activity against colon cancer. To evaluate the safety profile of MM-129, we …
Pharmacokinetics, biodistribution and antitumour effects of Sclerotium rolfsii lectin in mice
P Laha, M Sharma, K Pathak, S Bane… - Oncology …, 2017 - spandidos-publications.com
Sclerotium rolfsii lectin (SRL) is a lectin isolated from the fungus Sclerotium rolfsii and has
exquisite binding specificity towards the oncofetal Thomsen-Friedenreich antigen (TF-Ag; …
exquisite binding specificity towards the oncofetal Thomsen-Friedenreich antigen (TF-Ag; …
Systemic Administration of the Cyclin‐Dependent Kinase Inhibitor (S)‐CR8 Selectively Reduces Escalated Ethanol Intake in Dependent Rats
SP Goulding, G de Guglielmo… - Alcoholism: Clinical …, 2019 - Wiley Online Library
Background Chronic exposure to ethanol (EtOH) and other drugs of abuse can alter the
expression and activity of cyclin‐dependent kinase 5 (CDK5) and its cofactor p35, but the …
expression and activity of cyclin‐dependent kinase 5 (CDK5) and its cofactor p35, but the …
LC-MS/MS method for determination of cyclin-dependent kinase inhibitors, BP-14 and BP-20, and its application in pharmacokinetic study in rat
J Široká, M Čečková, L Urbánek, V Kryštof… - … of Chromatography B, 2018 - Elsevier
Abstract N 2-(4-Amino-cyclohexyl)-9-cyclopentyl-N 6-(6-furan-2-yl-pyridine-3-ylmethyl)-9H-
purine-2, 6-diamine (BP-14) and 2-(5-{[2-(4-amino-cyclohexylamino)-9-cyclopentyl-9H …
purine-2, 6-diamine (BP-14) and 2-(5-{[2-(4-amino-cyclohexylamino)-9-cyclopentyl-9H …
[图书][B] Investigation of checkpoint adaptation in human cancer cells treated with the genotoxic agent cisplatin
LH Swift - 2015 - search.proquest.com
We investigated checkpoint adaptation in HT-29 human colorectal adenocarcinoma cells
treated with cisplatin. Cells that undergo checkpoint adaptation arrest at and then abrogate …
treated with cisplatin. Cells that undergo checkpoint adaptation arrest at and then abrogate …